Protocols · Metabolic
GLP2 is the research code name for tirzepatide, sold as Mounjaro and Zepbound. This page covers that one compound only. Its published escalation ladder differs from the single-receptor GLP1 ladder, which is exactly why the two are kept on separate pages.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Dual-receptor trials report larger metabolic effect sizes than single-receptor arms.
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Tirzepatide · 10 mg Vial
Tirzepatide Dosage calculations for a 10 mg vial use the same once-weekly escalation amounts evaluated in human research and listed in the current product information. Adding 2 mL in this lyophilized-vial calculation produces 5 mg/mL, so each U-100 unit contains 50 mcg.
| Study Phase | Weekly Amount | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 50 units | 0.5 mL |
| Weeks 5 to 8 | 5 mg | 100 units | 1 mL |
| Weeks 9 to 12 | 7.5 mg | 150 units | 1.5 mL |
| Weeks 13 to 16 | 10 mg | 200 units | 2 mL |
| Weeks 17 to 20 | 12.5 mg | 250 units | 2.5 mL |
| Weeks 21+ | 15 mg | 300 units | 3 mL |
The same arithmetic for every vial size GLP2 (tirzepatide / Mounjaro) is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
GLP2 (tirzepatide / Mounjaro) · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit |
|---|---|---|
| 5 mg | 1.67 mg/ml | 17 mcg |
| 10 mg | 3.33 mg/ml | 33 mcg |
| 15 mg | 5.00 mg/ml | 50 mcg |
| 20 mg | 6.67 mg/ml | 67 mcg |
| 30 mg | 10.00 mg/ml | 100 mcg |
| 40 mg | 13.33 mg/ml | 133 mcg |
| 50 mg | 16.67 mg/ml | 167 mcg |
| 60 mg | 20.00 mg/ml | 200 mcg |
| 100 mg | 33.33 mg/ml | 333 mcg |
| 120 mg | 40.00 mg/ml | 400 mcg |
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Research vials are typically 5 mg, 10 mg or 15 mg lyophilised. A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL, so one U-100 unit carries 50 mcg.
Open the reconstitution calculatorThese are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine · 2022 · PMID 35658024
2539 adults with obesity were randomized to once-weekly subcutaneous tirzepatide at 5, 10, or 15 mg or placebo for 72 weeks (SURMOUNT-1 trial).
View the recordFrias JP, Davies MJ, Rosenstock J, et al. · New England Journal of Medicine · 2021 · PMID 34170647
Patients with type 2 diabetes were randomized to once-weekly tirzepatide (5, 10, or 15 mg) versus semaglutide 1 mg for 40 weeks (SURPASS-2 trial).
View the recordPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.
